Childhood Obesity Epidemic

BY LIZ HARROUN Due to rising rates of childhood obesity and diabetes in Texas, non-alcohol induced fatty liver disease is the number one need for transplant in young adults. We sat down with Dr. Poordad of the Texas Liver Institute to learn what is...

Read More

Dr. Eric Lawitz, of the Texas Liver Institute, Publishes on a New Standard of Care for Patients With Chronic Hepatitis C Infection and Severe Renal Impairment

Dr. Eric Lawitz, internationally recognized for his work in liver disease, published groundbreaking results from a Phase 3 study in patients with chronic hepatitis C infection and severe renal impairment.   The study was performed at the American Research Corp at the Texas Liver Institute, a world-renowned...

Read More
fibroscan, ultrasound elastography, fatty liver disease

Transient Elastography (FibroScan)

Transient Elastography (FibroScan) Non-Invasive Liver Fibrosis Assessment Accurately staging liver disease is important in the determination for and monitoring of a treatment regimen. A well-studied technology has become available to complement the clinical tests that are already used, called ElastPQ (FibroScan).  ElastPQ is a...

Read More

Next Generation HCV Therapy Presented at the International Liver Congress™ 2017 by Texas Liver Institute’s Dr. Fred Poordad | Company Newsroom of Texas Liver Institute

Study findings shed light on effective new HCV therapy that will treat patients who have failed other therapies San Antonio, Texas, April 27, 2017 (Newswire.com) – Dr. Fred Poordad, internationally recognized for his research in the field of liver diseases, presented a retreatment study...

Read More

AbbVie’s Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals

– 95 percent of patients achieved SVR12 with 12 weeks of ABT-493 and ABT-530 with and without RBV in GT1 chronic HCV infected patients without cirrhosis who failed previous therapy with DAAs in a modified intent-to-treat analysis – 91 percent achieved SVR12 with RBV...

Read More

DAAS in the Pipeline: What‘s coming?

http://medpagetoday.s3.amazonaws.com/media/sponsors/hothcv/Pipeline2.mp4 MedPage Today invited specialists from leading medical institutions to weigh in on the latest advancements in hepatitis C with one question each day for 10 days. In this installment, we asked: “DAAS in the pipeline: What’s coming?” Our participants are: Fred Poordad, MD,...

Read More

ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B) | BMS Newsroom

97% of post-transplant patients with HCV genotype 1a achieved cure 91% of post-transplant patients with HCV genotype 3 achieved cure   No need seen to alter existing transplantation medication regimens Saturday, April 25, 2015 10:00 am EDT (PRINCETON, N.J., APRIL 25, 2015) – Bristol-Myers...

Read More

AbbVie Receives U.S. FDA Approval of VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) for the Treatment of Chronic Genotype 1 Hepatitis C

– In Phase 3 clinical trials, VIEKIRA PAK cured 95-100 percent of hepatitis C patients, with less than 2 percent of patients experiencing virological failure – Tolerability profile shows more than 98 percent of patients completed a full course of therapy – All-oral interferon-free...

Read More

Obesity can lead to liver disease

It’s becoming health threat at young age When David Martinez was diagnosed with advanced cirrhosis of the liver, he was surprised and confused. “I thought cirrhosis came from drinking,” said Martinez, 50, a cable repair technician. “I asked the doctor, ‘Why is it that...

Read More